CXCL12 and cancer: Related to immunotherapy, the PARP inhibitor olaparib, used in the treatment of BRCA mutant cancers has been shown to have a beneficial impact on T‐cell targeting by modulation of SDF1α (CXCL12) production by CAFs [146].